The estimated Net Worth of Rebecca Chambers is at least 957 千$ dollars as of 21 June 2024. Ms Chambers owns over 260 units of Veracyte Inc stock worth over 293,619$ and over the last 4 years she sold VCYT stock worth over 55,713$. In addition, she makes 607,650$ as Exec. VP & CFO at Veracyte Inc.
Ms has made over 6 trades of the Veracyte Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 260 units of VCYT stock worth 11,957$ on 21 June 2024.
The largest trade she's ever made was exercising 16,727 units of Veracyte Inc stock on 24 June 2021 worth over 104,544$. On average, Ms trades about 2,620 units every 46 days since 2021. As of 21 June 2024 she still owns at least 9,684 units of Veracyte Inc stock.
You can see the complete history of Ms Chambers stock trades at the bottom of the page.
Rebecca Chambers is the Exec. VP & CFO at Veracyte Inc.
As the Exec. VP & CFO of Veracyte Inc, the total compensation of Ms Chambers at Veracyte Inc is 607,650$. There are 3 executives at Veracyte Inc getting paid more, with Bonnie H. Anderson having the highest compensation of 1,252,000$.
Ms Chambers is 43, she's been the Exec. VP & CFO of Veracyte Inc since . There are 7 older and 2 younger executives at Veracyte Inc. The oldest executive at Veracyte Inc is Dr. Tina S. Nova Ph.D., 67, who is the Pres of CLIA U.S. Bus..
Over the last 11 years, insiders at Veracyte Inc have traded over 201,983,044$ worth of Veracyte Inc stock and bought 75,122 units worth 1,149,322$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Nicole Vitullo、Jesse I Treu. On average, Veracyte Inc executives and independent directors trade stock every 20 days with the average trade being worth of 804,905$. The most recent stock trade was executed by John Leite on 4 September 2024, trading 5,479 units of VCYT stock currently worth 163,165$.
veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .
Veracyte Inc executives and other stock owners filed with the SEC include: